Corcept Therapeutics (NASDAQ:CORT) Issues Quarterly Earnings Results, Beats Expectations By $0.34 EPS

Corcept Therapeutics (NASDAQ:CORT) released its quarterly earnings results on Wednesday. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.34, FiscalAI reports. The business had revenue of $256.15 million during the quarter, compared to the consensus estimate of $221.15 million. Corcept Therapeutics had a return on equity of 8.48% and a net margin of 6.52%.The firm’s quarterly revenue was up 31.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.29 EPS.

Here are the key takeaways from Corcept Therapeutics’ conference call:

• Second-quarter revenue rose 32% to $256.1 million, while net income increased to $43 million. Management raised full-year 2026 revenue guidance to $1.1 billion–$1.2 billion, citing strength in both endocrinology and oncology.
• LIFYORLI generated $47.6 million in its first quarter of availability, with more than 1,300 patients initiating treatment and over 1,000 prescribing physicians. Management highlighted broad payer coverage, NCCN preferred-regimen status, and a goal of exceeding $1 billion in U.S. annual revenue for platinum-resistant ovarian cancer.
• Korlym and the authorized generic continued to benefit from record new prescriptions, prescribers, and active patients, with specialty-pharmacy transition issues largely behind the company. Corcept expects its Cushing’s syndrome business to reach at least $2 billion in annual revenue by the end of the decade.
• The FDA accepted relacorilant’s resubmitted Cushing’s syndrome application and assigned a December 17, 2026 PDUFA date. Management believes approval could accelerate growth, supported by positive Phase III data and the potential for a more favorable safety profile than existing treatments.
• Corcept reported encouraging development plans across oncology, MASH, and ALS, including upcoming data from BELLA, STELLA, TRIDENT, and MONARCH. However, dazucorilant’s ALS program still requires a dose-titration study because gastrointestinal side effects caused most discontinuations in the Phase II trial.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT traded down $3.59 during mid-day trading on Friday, reaching $114.73. The company had a trading volume of 814,336 shares, compared to its average volume of 1,597,610. Corcept Therapeutics has a one year low of $28.66 and a one year high of $122.21. The firm has a market cap of $12.32 billion, a price-to-earnings ratio of 272.64 and a beta of 0.47. The business’s 50-day simple moving average is $83.68 and its 200 day simple moving average is $56.37.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on CORT shares. Piper Sandler reissued an “overweight” rating and issued a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a research report on Thursday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a research report on Wednesday, June 24th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective for the company. in a research note on Monday. UBS Group set a $135.00 price objective on shares of Corcept Therapeutics in a report on Thursday, May 28th. Finally, Canaccord Genuity Group raised their target price on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $119.17.

Insider Buying and Selling at Corcept Therapeutics

In other news, Director David L. Mahoney sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $84.53, for a total value of $1,690,600.00. Following the completion of the transaction, the director directly owned 26,147 shares in the company, valued at approximately $2,210,205.91. The trade was a 43.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William Guyer sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $93.13, for a total transaction of $1,862,600.00. Following the sale, the insider directly owned 3,985 shares of the company’s stock, valued at approximately $371,123.05. This trade represents a 83.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 300,000 shares of company stock valued at $22,088,050 over the last three months. 20.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Advisory Services Network LLC bought a new stake in Corcept Therapeutics during the third quarter worth $25,000. Atlas Capital Advisors Inc. bought a new position in shares of Corcept Therapeutics in the 4th quarter valued at $31,000. Larson Financial Group LLC raised its holdings in shares of Corcept Therapeutics by 2,326.3% during the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock worth $38,000 after buying an additional 442 shares in the last quarter. Gould Capital LLC lifted its position in shares of Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after buying an additional 200 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its stake in Corcept Therapeutics by 128.5% in the third quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 433 shares in the last quarter. 93.61% of the stock is owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.